Summary Background Data Accelerated protein catabolism is a constant feature of the hypermetabolic response to thermal injury. Insulin-like growth factor-1 has been reported to minimize protein catabolism and normalize energy expenditure in animal models of thermal injury.
Methods
To determine the efficacy of IGF-1 in human burn patients, resting energy expenditure (metabolic cart), whole body protein kinetics (N 1 5 Lysine), and glucose disposal (glucose tolerance test) were assessed in eight burn patients before and after a 3-day infusion of IGF-1 (20 pg/kg/hr). All patients were fluid-resuscitated uneventfully and were without obvious infection at the time of study. Enteral nutrition was administered at a constant rate before and during the IGF-1 infusion.
Results
Resting energy expenditure was not altered by IGF-1 (40.3 ± 2.2 vs. 39.1 ± 2.3 kcal/kg/day). However, glucose uptake was promoted, and protein oxidation decreased significantly (0.118 ± 0.029 vs. 0.087 ± 0.021 g/kg/d, p < 0.05) by IGF-1. In addition, insulin secretion, in response to a glucose challenge, was blunted.
Conclusions
Insulin-like growth factor-1 therapy has a beneficial effect in preserving lean body mass during severe stress conditions by minimizing the flux of amino acids toward oxidation.
Accelerated protein catabolism is a constant feature of accelerated rate of protein breakdown. Attempts to limit the hypermetabolic response to thermal injury. Current catabolism by experimental treatment with growth hornutritional support regimens using high calorie and promone have been promising under certain conditions., 2 tein enteral or parenteral solutions do not completely reThe administration of pharmacologic doses of growth verse net protein catabolism and have little effect on the hormone to fasting adult humans resulted in a protein sparing effect, but has failed to stimulate protein syntheindirect calorimetry (Deltatrac, Sensor-Medics, Anasis in other studies.' Clinical trials using growth hormone heim, CA), and enteral feedings were initiated at a rate in a variety of catabolic conditions demonstrated that sufficient to meet the patients' estimated calorie and progrowth hormone was somewhat effective in conserving tein needs. The calorie-to-nitrogen ratio was maintained body proteins. 4 , 5 However, the most severely ill patients at 150 to 1. The enteral feedings were continued at the did not improve their nitrogen balance. In addition, same rate, protein content, carbohydrate content, and growth hormone is an insulin antagonist and may exfat content for the duration of the study. Oral intake was acerbate stress-induced insulin resistance.
not allowed during the study period. Excision and graftIn 1972, Daughaday proposed that growth hormone ing of the burn wounds were performed during this staregulates the hepatic synthesis and release of IGF-1, bilization period as required. After 3 days of stable nutriwhich is considered to be one of the potential mediators tional intake, the following studies were obtained: indiof the anabolic effects of growth hormone. 6 ' 7 In patients rect calorimetry, body weight measurements, serum who are critically ill, growth hormone has been shown to IGF-1, IGF-1 binding protein and glucose levels, 24-have reduced effectiveness in stimulating the release of hour urine samples for 3-methyl-histidine, urinary urea IGF-1, thus, possibly explaining the failure of growth nitrogen and total urinary nitrogen excretions, intravehormone to reverse catabolism in some patients. 8 Data nous glucose tolerance tests, and " 5 N Lysine studies to confirming the role of IGF-I in the regulation of growth, measure whole body protein oxidation and degradation. metabolism, and differentiation have expanded remarkAfter completion of these baseline studies, an intraveably during the last decade, and the recent availability nous infusion of IGF-1 at a rate of 20 ag/kg/hr was of recombinant IGF-1 has provided the opportunity to started for each patient. Serum glucose levels were obstudy its biologic potential. 9 Diet and tumor necrosis factained at the 1/2-, 1-, 4-, and 6-hour time points after initor-induced catabolism have been reversed by exogenous tiation of the IGF-1 and every 6 hours thereafter. After 3 IGF-1 in animal and human studies.1°-4 More impordays of therapy, all baseline studies were repeated. tantly, IGF-1 has been shown to limit postburn hyperFor each patient, a modified intravenous glucose tolmetabolism and reduce gut atrophy and bacterial transerance test was performed by administering a 50% aquelocation in rodent models after severe burn injury, sugous glucose solution (0.5 g/kg ideal body weight) for 90 gesting a potential role for this compound in the seconds. Four milliliter-blood samples for insulin and treatment of patients with thermal injury.15"1 6 glucose levels were obtained before the bolus and at 10, The purpose of this trial is to determine the effects of a 20, 30, 40, 60, 90, 120 and 150 minutes after the glucose continuous infusion of recombinant human IGF-1 on challenge. The enteral feedings were not stopped during the catabolic response to thermal injury in adult burn this study, and this was the only intravenous glucose that patients.
the patients received.
To estimate whole body protein oxidation and degra-METHODS dation, the 15N Lysine technique, as described by Wolfe, was used.' 7 The 15N Lysine was infused continuously at Study Protocol a rate of 0.08 Atmol/kg/min immediately after a priming Eight adult patients with burns of more than 25% of dose of 6.8 Amol/kg. In addition, the urea pool was their body surfaces, who were admitted to the U.S. Army primed by administration of 3.2 pmol/kg of N-14,15
Institute of Surfac es e r ttedrn center at Arm urea. Sterile nonpyrogenic amino acid was dissolved in Medical College of Virginia within 48 hours centerat sterile saline, and the solution was infused at a rate that h of injury, did not exceed 25 mL/hr. After 1 hour of constant infuwere enrolled. After obtaining informed consent, a medsion, plasma samples were obtained every hour for 3 ical history was elicited and a baseline physical examinahous Hlys rn samples were colleed dur this tionwasperfrme foreac paient Wihin 2 hurs hours. Hourly urine samples were collected during this tion was performed for each patient. Within 72 hours tie of injury, resting energy expenditure was measured by
Analysis of Samples
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Whole blood was collected in ice-cold heparinized = lysine oxidation (Amol/kg/min) X 2.647.
Lysine oxidation was calculated from the rate of ap-RESULTS pearance of labeled urea in the urine (urea Ra [rate of appearance]) and the plasma enrichment of " 5 N Lysine Eight patients were enrolled in the study; mean age and " 5 N urea. and burn size were 41.6 ± 5.6 years and 56 ± 6.5%, reLysine oxidation (Amol/kg/min) = (urea Ra) spectively. All patients completed the protocol, and no untoward effects of the IGF-1 were noted. Specifically, (% urea enrichment/% lysine enrichment).
symptomatic hypoglycemia did not occur in any patient, Urea Ra (tmol/kg/min) = (urine N) (urine volume) although one patient had a serum glucose of 58 mg/dL coincident with the stoppage of enteral feedings second-(1.2)/(weight) (urine time) (2.8 gm/utmol) ary to tube dislodgement. All patients had a significant assuming that 20% of urea is recycled. '8 rise in their serum IGF-1 levels with a concomitant decrease in growth hormone levels while receiving IGF-1.
The rate of protein degradation (g/kg/day) was estimated Circulating levels of IGF-1 binding proteins 2 and 3 also from the rate of appearance of endogenous lysine (Lysine were increased (Table 1 ). Resting energy expenditure did Rae) in the plasma: not change during treatment (40.3 ± 2.2 vs. 39.1 ± 2.3 kcal/kg/day), and all patients demonstrated a significant increase in resting energy expenditure over normal (TaLysine Ra = lysine Ra -lysine in enteral feedings.
ble 2). Insulin and C-peptide levels were depressed significantly from baseline values by the IGF-1 infusion. Glu-(gmol/kg/min) X 99%/% lysine enrichment cose and fat oxidation rates were not altered by the IGF-1 (Table 3) . The glucose tolerance test (GTT) confirmed The plasma insulin and glucose levels from the glucose the insulin-like properties of the IGF-1 in this patient cotolerance test were plotted, and the area under each curve was calculated to yield an estimate of the disposal of glucose and the amount of insulin secretion prompted by the glucose bolus. The rate of glucose and fat oxida- Table 2 . REE VALUES BEFORE AND tion (g/min) were estimated from the indirect calorime-DURING IGF-1 try data using the following formulae: Insulin has been documented to improve nitrogen balhort. Insulin secretion, as indexed by the area under the ance in trauma patients, although this effect has been reinsulin curves, was suppressed significantly by the IGFported to be short lived by some.
'
27 Jahoor and col-1 infusion during the GTT in six of the eight patients.
leagues have demonstrated an intact insulin response in However, the area under the glucose curves was not patients who are burned and septic patients. 28 In these affected by the IGF-1, indicating the same level of glupatients, the maximal effectiveness of insulin to suppress cose disposal despite the blunted insulin response. Two protein breakdown was intact but was insufficient to norpatients demonstrated little suppression despite elevated malize the negative flux of amino acids. Of particular serum levels of IGF-1 (Fig. IA-D) .
note was the dose of insulin required to achieve these No patient was in positive nitrogen balance during the results; 500 mU/m 2 /min or approximately 52 units/hr. study period. Nitrogen balance did become slightly less
The safety of such high-dose insulin therapy in terms of negative during the IGF-1 infusion, although this differmaintaining euglycemia in a critically patient in an ICU ence was not significant (Table 4 ). lysine oxidation deenvironment is a persistent clinical concern. creased significantly during the IGF-1 infusion from
The 1974 report by Wilmore et al. that states that 0.0447 ± 0.011 Amol/kg/min to 0.033 ± 0.0089 umol/ growth.hormone increased nitrogen retention in patients kg/min (p < 0.05). Lysine Rae also decreased during with thermal injury and receiving adequate calories and IGF-1 therapy from 3.089 ± 0.39 pmol/kg/min to 2.52 nitrogen 29 sparked interest in this treatment modality. + 0.38 pmol/kg/min (p = 0.059).
These direct anabolic actions subsequently have been reported in pediatric burn patients, postoperative patients, DISCUSSION patients with chronic obstructive pulmonary disease, patients receiving parenteral nutrition, and healthy volunThe recognition by Cuthbertson in the 1930s 20 that teers treated with steroids. 1 ,2,3°-32 Basal levels of growth even relatively minor trauma results in hypermetabohormone and IGF-1 have been reported to be low after lism and a state of catabolism characterized by negative thermal injury. 33 Resistance to the anabolic effects of nitrogen balance has prompted investigators to search growth hormone has been reported, especially in those for means of promoting anabolism and preventing capatients with the most severe injury. 5 This 'lack of effect tabolism to improve the treatment of the injured. This appears to be secondary to a failure of growth hormone self-induced state of "autocannibalism," the extent of to elicit an IGF-1 response. This, in concert with the negwhich is quite severe in burn patients, can result in a sigative effects of growth hormone such as increased lipolynificant loss of lean body mass. Although short-term sis and insulin antagonism, make it a relatively unattracbenefits of this self-destructive response to injury have tive candidate with which to counter post-injury catabobeen postulated, the long-term muscle wasting and imlism.
34
' 35 paired immune response have a significant impact on Reports that implicate IGF-1 as the mediator of the outcome and recovery because survival rates have been anabolic effects of growth hormone and others that demreported to be inversely proportional to the loss of lean onstrate that basal levels of both growth hormone and body mass. down and promoting protein synthesis. 10, 1136 In attally reverse the catabolic state because all patients retempts to partially mimic the hormonal milieu of injury, mained in negative nitrogen balance, similar to the other investigators have studied the effects of IGF-1 in effects of insulin reported by Jahoor. 28 We cannot comanimals pretreated with dexamethasone or tumor necroment on whether protein synthesis was affected because sis factor." 4 ' 37 In both cases, the anabolic effects of IGF-1 incorporation of ' 5 N into muscle was not measured, alwere preserved, indicating a potential role for this comthough IGF-1 has been reported to increase protein synpound in the treatment of injured man. In normal volthesis in vitro. 39 unteers, IGF-1 has been shown to reduce nitrogen wastInsulin-like growth factor-1 treatment significantly ining by decreasing protein breakdown and oxidation hibited glucose-stimulated insulin secretion, a finding rewhile inhibiting insulin secretion and promoting glucose ported by others, while maintaining glucose disposal. However, IGF-1 did not increase oxidative and nonoxiWe have documented that the short-term anabolic dative glucose disposal in this group of severely stressed effects of IGF-1 are preserved after severe thermal injury patients as has been reported in normal volunteers. 40 A in a group of patients who were receiving full nutritional similar finding has been reported in fasted lambs, in support. Insulin-like growth factor-1 inhibited lysine oxwhich a low-dose infusion of IGF-1 resulted in a protein idation significantly while decreasing protein breakdown sparing effect without an increase in glucose oxidation. 36 despite the inhibition of insulin secretion. It did not toThat this lack of effect on glucose oxidation represents a dosing phenomena is supported by the study of Jahoor bolic patients because IGF-1 has been shown to decrease and co-workers, in which they documented that the pehepatic protein synthesis, whereas growth hormone has ripheral effect of insulin on glucose metabolism is intact the opposite effect.44 Moreover, the addition of IGF-I to in patients with thermal injury and that in the aforemengrowth hormone therapy may abrogate the negative tioned lamb study, a higher dose of IGF-1 resulted in effects of growth hormone, such as insulin resistance and both protein sparing and increased glucose oxidation.
8 its lipolytic effect. The inhibition of insulin secretion by IGF-1 was not
The clinical implications of these effects may be sublinked to its protein-sparing effect as shown in two pastantial because IGF-1 has been shown to improve tients in whom IGF-1 did not suppress insulin secretion wound healing in corticosteroid-treated rats and reduce but did promote protein sparing. This dichotomy is pargut atrophy and bacterial translocation in an ovine ticularly confusing because it is believed that both the model of thermal injury.1 6 ' 4 5 Extrapolation of our short-IGF-l-mediated inhibition of insulin secretion and the term infusion data suggests a potential sparing of 3.24 kg protein-sparing effects of IGF-I are mediated via IGF-I of lean body mass, or almost 5% of body weight, in a 70-receptors, although some investigators have suggested kg adult during the initial 30 days after injury. The lack that the protein-sparing effects are mediated via insulin of untoward effects in our patients and the fact that eureceptors. 4° glycemia was maintained by provision of only 5 mg/kg/ Unlike the findings in an animal study,' 5 we did not min of enteral glucose would indicate that IGF-I potenobserve an effect of IGF-I on resting energy expenditure.
tially is safer than insulin. In light of the complicationsThis is not surprising because glucose and fat oxidation both acute and long term-of autocannibalism of lean rates were maintained at pretreatment levels, and others body mass, treatment with IGF-1 holds promise as a have reported the lack of an lipolytic effect of IGF-1. 41 In means to improve the metabolic support of injured perlight of that and because protein oxidation accounts for sons, shorten hospital stay, and accelerate convaonly a small fraction of the resting energy expenditure, lescence. one would not expect a significant impact of the IGF-1 on the metabolic rate of these patients.
Circulating levels of IGF-1 binding proteins 2 and 3 Dr. Cioffi and his associates tried to shift the balance between Second, the measurements in this group of patients were anabolism and catabolism in recovering burn patients by infusmade while enteral feedings of a high calorie-high nitrogen diet ing IGF-1, an anabolic hormone. The good news is thatwere being administered. As you know, many studies of the amazingly-it looks as though maybe they did it. metabolic response to injury were carried out after at least an IGF-I infusion appeared to inhibit the erosion of body proovernight fast by the study subjects. Do you feel that your findtein by reducing the use of protein as a fuel for oxidation and, ings would have been different if derived during fasting? And if as Dr. Cioffi indicated, over the course of recovery from a major so, how? burn this might spare several kilograms of lean body mass and Third, and along the same lines, do you feel that IGF-1 adthus reduce the debility associated with recovery. ministration might be dangerous if given in the absence of exBut before we rush to adopt IGF-1 as a routine therapy in ogenously administered substrate in that what is at least an our ICUs, we should consider some of the possible limitations early survival metabolic response could be diminished? For exof the study. ample, could patients become dangerously hypoglycemic?
First, the isotopic dilution techniques are most reliable when Finally, I would like to thank the Association for the privilege a variety of fairly strict conditions are met. The size of the comof membership.
partments or pools in which the isotope is distributed should be constant during both studies; the isotopic distribution should DR. DAVID N. HERNDON (Galveston, Texas): I would like to be in a steady state; and recycling should be negligible or cerjoin Dr. Goodwin in congratulating the authors on an excellent tainly constant. The metabolic state of a recovering burn paclinical research study that clearly demonstrates that this newly tient is certainly a dynamic one as he or she progresses toward available recombinant product has a small but significant effect recovery, so that the conditions under which these two studies of decreasing lysine oxidation in hypermetabolic burn patients were accomplished might well be different.
over a 3-day infusion period. Dr. Cioffi, could the differences you observed in lysine kinetThis as3-day titisusio n i sio n tics be due in part to progression of the patient's convalescence? This study titillates us in its conclusion to speculate that this InohrwdsiftepinsddntrcivIG-wulte agent might have clinical utility. The introduction of any modIn other words, if the patients did not receive IGF-1 would the ulator of the host response should address risk benefits, includresults of isotopic dilution studies done in 3-day intervals be ing discussions of potential alternatives. And in that regard I constant or would they show similar changes?
would like to ask three questions. .Secondly, when you look at how all these parameters are deAstoclinIwould like to ask thre q , trived or calculated through the formulas in the manuscript, you As to clinical efficacy, I would like to ask the authors to comment on recent reports that demonstrate that when IGF-1 is realize that the parameters here, protein oxidation and protein given for chronic periods to AIDS patients there is an initial breakdown, are really derived from just a few primary meaanabolic effect on protein metabolism but this effect disappears surements. In addition to measurements of isotopic enrichin the second and third week of treatment, presumably due to values of the intake of the unlabeled lysine and also on the outreciprocal increase in binding proteins which limits free IGF-1 availability. How would you prevent binding protein producput of urea nitrogen. Lysine intake came from absorption of tion from negating the effects of IGF-1 over time?
lysine from the enteral feeding in the GI tract. This was asIn terms of risk, could you comment on the decision of the sumed to be constant during these studies. Although the meamajor pharmaceutical suppliers of IGF-I to suspend the availsurements of urea nitrogen and total nitrogen is standard, there ability for clinical trials of the agent because of five cases of was enough variability in the system that nitrogen balance was Bell's palsy and three cardiac arrests in patients being studied? not statistically different before and after IGF-1.
Finally, insulin and insulin-like growth factor-1 exert their When there are significant differences in the derived paramanabolic effects through related if not in some cases identical eters but not in the primary data on which they are based, we must be cautious in our interpretation of the data. Dr. Cioffi, membrane receptors. One of the co-authors of this paper has wuld yo commen furterpon this?
shown a twofold improvement in protein synthesis, in fact a would you comment further on this?
more dramatic improvement than shown with IGF-1, with inBut nonetheless, the burn patient is certainly the biggest metsulin infusions in patients that are quite similar to those studied abolic challenge we face and the fact that Dr. Cioffi and his here. Might the authors be able to subserve the same therapeuassociates detected improvement in protein metabolism with IGF-I is an exciting finding and offers the possibility of further tic anabolic function at a lower risk and a lower price with inrdcn h aaoi oto rtcliles sulin than the newly available recombinant product?
reducing the catabolic cost of critical illness.
DR. JOSEF E. FISCHER (Cincinnati, Ohio): Those of us who DR. PALMER Q. BESSEY (Rochester, New York): I, too, have struggled in the area of proteolysis have probably relucwould like to rise to congratulate Dr. Cioffi and his associates tantly begun to come to the conclusion that one of the probfor completing these sophisticated metabolic studies in a group lems in the proteolytic situation is not the presence of positive of very difficult, complex, critically ill patients, factors that increase proteolysis but the absence of positive fac-tors such as IGF-1. My simpleminded way of looking at this is protein oxidation equates to a very small number of calories, that perhaps what IGF-1 does is decrease transport of amino and thus I would not expect to find a difference in resting energy acids from the periphery to the center, expenditure. If data are correct, and assuming that you have a 70-kilogram Dr. Goodwin also asked about the use of fasting versus fed man, I calculated from the differences in protein, fat, and glupatients. Indeed, it is preferable to perform metabolic studies cose oxidation that there is a difference over 24 hours of about in a fasting state. However, the hypoglycemic response that you 69 calories expended in a 70-kilogram man. So it is not surpriswould anticipate at the infusion of 20 micrograms per kilogram ing that a resting energy expenditure did not detect the differper hour of IGF-1 would be prohibitive. Thus, similar to the ence in this particular group of patients.
insulin studies that Dr. Herndon alluded to, you need to supply On the other hand, I wonder-and Cleon Goodwin has ala constant glucose infusion. ready referred to this-whether you stack the deck against
The safety of the compound, IGF-1, was questioned by both yourselves by giving these people and continuing 5 milligrams Dr. Herndon and Dr. Goodwin. Indeed, there have been sevper kilogram a minute of carbohydrate by enteral feeding, eral incidences of Bell's palsy and cardiac arrest in other patient which remained stable throughout the experiment, and populations that have been studied using IGF-l. We did not whether the difference between the animal experiments, which note any untoward effects in our patients. The majority of comshow efficacy of IGF-I under these circumstances, and huplications that have been documented, that Dr. Herndon mans, is the fact that the animals were fasted, or at least were noted, occurred in a group of AIDS patients and a group of not fed to excess, and here you had no alternative but to consevere insulin-dependent diabetics that were receiving much tinue the feeding. sever diabetics than werereceivngred. One possible way around this, since it would be unethical higher doses ofIGF-1 than we administered. and you wouldn't want to decrease the feedings for a prolonged Dr. Herndon asked about the ze s iof the protein-sparing period of time in patients with these extensive burns, is perhaps effect, and was it enough to really make a clinical difference. He to go back to an old technique which I know is available in the also asked if we could obtain the same effect as Dr. Gore had laboratory-amino acid fluxes in the unburned extremities, if previously published using higher doses of insulin. I think that such existed-in which if you fasted the patients maybe for 6 the size of the effect that we documented is substantial if we hours you probably would see the effect of IGF-1 on muscle take the lysine data and extrapolate it to whole body protein amino acid flux and perhaps prove your point, kinetics and then look at what would happen over the initial 30 I do have another problem, and that's with the calculation of days postburn period. glucose oxidation. Since you obviously have the capacity for
The purpose of the IGF-1 infusion was not to decrease restisotopic dilution, wouldn't it be better to derive the glucose oxing energy expenditure of the patients, but to decrease the autoidation figures from a direct test of glucose oxidation enrichcannibalism of lean body mass and attempt to keep protein ment than an indirect calculation? I think it would make a very stores, both functional and structural, intact. nice paper and a very nice series of studies even nicer.
If we wanted to use insulin instead of IGF-1, I think there It's a very nice manuscript and it was an excellent presentaare several problems with that approach. The study that Dr. tion.
Herndon alluded to pointed out some of those problems. In order to halve the protein oxidation rates with insulin, it re-DR. STANLEY M. LEVENSON (Bronx, New York): Just one quired 52 units of insulin per hour and the administration of brief comment. The data presented by Dr. Cioffi are very sug-12 milligrams per kilogram per minute of glucose to those pagestive, but from the point of view of experimental design of tients. the study, I would have liked to have seen an equal group of I would hesitate to use that as a standard therapy in any insimilar patients studied concurrently but prospectively rantensive care unit where I would think the complications associdomized in a double-blind study to have received only the veated with hypoglycemia would be immense, and certainly hicle in which the insulin-like growth factor-1 was solubilized. much worse than they were noted to be in this study. The reason for my suggestion is that these patients were studAn additional effect of insulin is that very small infusion rates ied at a time when their clinical and metabolic states may well result in essentially shutting off hepatic gluconeogenesis. IGFbe changing. I am not saying that what has been demonstrated 1 has been noted to have a similar effect, but at much higher by Dr. Cioffi and his colleagues is not the case, but their condoses, and I would hope that at the dose we employed in this clusion regarding the effects of the insulin-like growth factor-1 study we would not observe this effect. would be significantly more solid had there been an appropriate Dr. Bessey alluded to some of the limitations of using isotocontrol group of patients studied concurrently. pic techniques to do these studies. I can only say that during the time period the patients were studied, their weights were stable, DR. WILLIAM G. CIOFFI (Closing discussion): I would like to they were on a stable nutritional diet, and they received no exthank the discussants for their questions, and I will answer ogenous nutrition other than the enteral feedings. As he noted, them in the order that they were asked.
however, we cannot be sure they absorbed all the enteral lysine Dr. Goodwin asked three questions, the first concerning the which we presented to them. changes in glucose, fat, and protein oxidation, and why there
In terms of the stability of the resting energy expenditure and was no observed change in resting energy expenditure. I think nitrogen metabolism in these patients, we previously reported that Dr. Fischer answered that question, in that the decrease in that from postburn day 4 or 5 until at least the 30th postburn day, resting energy expenditure and nitrogen wasting is essenfor the present time and we are going to have to wait and see if tially stable in this kind of burn patient.
we can get more compound. Dr. Bessey also asked about the nitrogen balance data not Again, I think the most important point of the study is that being statistically different between the two groups. That data we were not looking to decrease resting energy expenditure, but was calculated using 24-hour urine collections, while the isowe were hoping to preserve lean body mass. I think we demontope data was calculated over a 3-hour time period of the isostrated that we can do that with IGF-1 in thermally injured tope infusion. I think the urine collections during the 3-hour patients. study are much more accurate than the 24-hour urine collecDr. Herndon, I think, had the most crtical comment, and tions in the intensive care unit.
Dh. Hernd I do the m ost itin?" Indeed, and Dr. Fischer asked why we did not use glucose isotopes rather that is "Could we do the same with insulin?" Indeed, the two than the metabolic cart data. I agree with him that it would be compounds work in a very similar fashion. IGF-1 does bind a much better study if we were able to use the glucose isotopes.
insulin receptors, and many of its effects are then modulated by We started this as a pilot and we were hoping to see if we could the insulin receptor. However, I think in terms of clinical utildocument a protein-sparing effect of the IGF-1 and then go on ity, IGF-1 would be a much safer drug to use in an intensive to look at its effects on glucose oxidation in a much more precare unit in terms of symptomatic hypoglycemia. As I noted, it cise way. As Dr. Herndon commented, both Genentech and takes exceptionally high doses of insulin to get the same kind of Ciba Geigy have withdrawn the compound from the market effect that we noted with relatively modest doses of IGF-1.
